SCD is a fund I've provided coverage on quite regularly as it's a unique fund. The fund carries a portfolio of MLPs and tech as its largest weightings though it is somewhat diversified overall, too, ...
Heightened market volatility presents unique buying opportunities for income investors, particularly in the technology and energy sectors, which show signs of bottoming as Q1 earnings season ...
A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...
A cross-sectional analysis assessed the birth prevalence of sickle cell disease (SCD) alongside data on social vulnerability to highlight the needs of communities impacted by SCD. SCD, a blood ...
NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...
The Punch on MSN
Sickle cell and moving forward with gratitude, hope
As the year opens up, many of us living with sickle cell disease find ourselves in a reflective space. Gratitude at the beginning of the year is not simply a list of blessings; for people living with ...
The world’s first CRISPR-based gene-editing therapy appears to be nearing the market. And an influential drug cost watchdog has an early idea of how the treatment should be priced to be considered ...
Groundbreaking? Game-changing? Transformational? Historic? None of the buzzwords sound adequate to describe Friday’s FDA approval of Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy (exa-cel) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback